<DOC>
	<DOCNO>NCT01853033</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics ABT-122 subject Rheumatoid Arthritis .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Pharmacokinetics Multiple Subcutaneous Injections ABT-122 Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description>This phase 1 , randomize , double-blind , placebo-controlled , multiple ascend dose study . Twenty-four subject Rheumatoid Arthritis select participate . Subjects randomize receive either ABT-122 placebo . ABT-122 placebo administer subcutaneous ( skin ) injection three dose group .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Diagnosis Rheumatoid Arthritis ( RA ) &gt; 3 month . On methotrexate ( MTX ) therapy = &gt; 3 month stable dose least 4 week . Except MTX , must discontinue diseasemodifying antirheumatic drug ( DMARDs ) least 3 month 5 halflives , whichever longer . Body Mass Index ( BMI ) 19 38 , inclusive . Other RA , subject good general health . Evidence antiABT122 antibody serum sample take Screening . History significant allergic reaction ; history anaphylactic reaction agent ; history major reaction IgG contain product . History persistent chronic active infection ( ) require hospitalization treatment intravenous oral antimicrobials/antibiotics within past 30 day . History evidence active tuberculosis ( TB ) subject evidence risk factor latent TB . Subject medical condition illness RA well control treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Tolerability</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>